Exclusive Summary

• This methylene blue injection, with US FDA approval, USP standards, and existing US registration, boasts high international quality certification and compliance, laying a solid foundation for global market access.
• Methylene blue is a WHO essential medicine for methemoglobinemia and cyanide poisoning, with clear global clinical demand and guideline recommendations, ensuring a stable patient base.
• In the global market, particularly where originator patents have expired, this product offers strong cost competitiveness, attracting healthcare institutions and governments seeking cost-effective medicines.
• The current generic market may not be saturated, or there could be specific regional market gaps, providing favorable opportunities for new entrants.
• Leveraging existing US registration experience and GMP certification, the product can rapidly expand into other international markets with stringent quality requirements, reducing re-registration barriers.